Clinical efforts to combine endocrine agents with targeted therapies against epidermal growth factor receptor/human epidermal growth factor receptor 2 and mammalian target of rapamycin in breast cancer

Clinical Cancer Research

Volumn 12, Issue 3 II, 2006, Pages

  Johnston, Stephen R D ^a,b   Arteaga, Carlos ^c   Winer, Eric ^c   Dowsett, Mitch ^c   Kumar, Rakesh ^c   Come, Steven ^c  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; BORTEZOMIB; CANERTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; ESTROGEN RECEPTOR; EVEROLIMUS; FULVESTRANT; GEFITINIB; LAPATINIB; LONAFARNIB; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PLACEBO; PROTEIN KINASE B; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; SUNITINIB; TAMOXIFEN; TEMSIROLIMUS; TIPIFARNIB; TRASTUZUMAB;

BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER STAGING; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; DRUG POTENTIATION; DRUG TARGETING; ENZYME ACTIVATION; ESTROGEN DEFICIENCY; HORMONAL THERAPY; HUMAN; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; HUMANS; PROTEIN KINASES; RANDOMIZED CONTROLLED TRIALS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

EID: 32944466881     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2125     Document Type: Conference Paper

References (42)

1. Nicholson RI, McClelland RA, Robertson JRF, Gee JMW. Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer 1999;6:373-87.
2. Johnston SRD. Combinations of endocrine and biological therapies; present status of therapeutic and presurgical studies. Clin Cancer Res 2005;11:889-99s.
3. Knowlden JM, Hutcheson IR, Jones HE, et al. Elevated levels of epidermal growth factor receptor/cerB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 2003;144:1032-44.
4. Jeng MH, Yue W, Eischeid A, Wang J-P, Santen RJ. Role of MAP kinase in the enhanced cell proliferation of long-term estrogen deprived human breast cancer cells. Breast Cancer Res Treat 2000;62:167-75.
5. Nicholson RI, Hutcheson IR, Knowlden JM, et al. Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination. Clin Cancer Res 2004;10:346-54s.
6. Gee JM, Harper ME, Hutcheson IR, et al. The anti-EGFR agent gefitinib (ZD 1839/Iressa) improves anti-hormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 2003;144:5105-17.
7. Okubo S, Kurebayashi J, Otsuki T, Yamamoto Y, Tanaka K, Sonoo H. Additive antitumour effect of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) and the antioestrogen fulvestrant (Faslodex, ICI 182,780) in breast cancer cells. Br J Cancer 2004;90:236-44.
8. Kurokawa H, Lenferink AEG, Simpson JF, et al. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res 2000;60:5887-94.
9. Shou J, Massaraweh S, Osborne CK, et al. Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst 2004;96:926-35.
10. Massarweh S, Shou J, Mohs-n SK, et al Inhibition of epidermal growth factor HER2 receptor signaling using ZD1839 (Iressa) restores tamoxifen sensitivity and delays resistance to estrogen deprivation in HER2-overexpressmg breast tumors. Proc Am Soc Clin Oncol 2002;21:33a (A130).
11. Albain K, Elledge R, Gradishar WJ, et al. Open-label phase II multicenter trial of ZD1839 (Iressa) in patients with advanced breast cancer. Breast Cancer Res Treat 2002;76:A20.
12. Baslega J, Albanelli J, Ruiz A, et al Phase II and tumor pharmacodynamic study of gefitinib in patients with advanced breast cancer Proc Am Soc Clin Oncol 2003;22:A24.
13. Robertson JFR, Gutteridge E, Cheung KL, et al. Gefitinib (ZD1839) is active in acquired tamoxifen-resistant oestrogen receptor positive and ER-negative breast cancer: results from a phase II study. Proc Am Soc Clin Oncol 2003;22:A23.
14. Gee JM, Gutteridge E, Robertson JF, Wakeling AE, Jones HE, Nicholson RI. Biological markers during early treatment of tamoxifen-resistant breast cancer with gefitinib ("Iressa"). Breast Cancer Res Treat 2004;8: S32 (A307).
15. Polychronis A, Sinnett HD, Hadjiminas D, et al. Pre-operative gefitinib versus gefitinib and anastrozole in postmenopausal patients with breast cancer: a double-blind placebo-controlled phase II randomised trial. Lancet Oncol 2005;6:383-91.
16. Winer E, Cobleigh M, Dickler M, et al. Phase II multicenter study to evaluate the efficacy and safety of Tarceva (erlotinib. OSI-774) in women with previously treated locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2002;76:A445.
17. Tan AR, Yang X, Hewitt SM, et al. Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor. J Clin Oncol 2004;22:3080-90.
18. Guix M, Kelley MS, Reyzer ML, et al. Short course of EGF receptor tyrosine kinase inhibitor erlotinib (OSI-774) reduces tumor cell proliferation and active MAP kinase in situ in untreated operable breast cancers: a strategy for patient selection into phase II trials with signaling inhibitors. Proc Am Soc Clin Oncol 2005;23:194s (A3008).
19. Witters LM, Engle L, Lipton A. Restoration of estrogen responsiveness by blocking the HER2/neu pathway Oncol Rep 2002;9:1163-6.
20. Argiris A, Wang C-X, Whalen SG, DiGiovanna MP. Synergistic interactions between tamoxifen and trastuzumab (Herceptin). Clin Cancer Res 2004;10:1409-20.
21. Marcom PK, Isaacs C, Harris L, et al. A phase II trial of letrozole and trastuzumab for ER and/or PgR and HER2 positive metastatic breast cancer: final results. Proc Am Soc Clin Oncol 2005;23:27s (A596).
22. Arpino G, Weiss H, Wakeling AE, Osborne CK, Schiff R. Complete disappearance of ER+/HER2+ breast cancer xenografts with the combination of gefitinib trastuzumab, and pertuzumab To block HER2 crosstalk with ER and restore tamoxifen inhibition. Breast Cancer Res Treat 2004;88:315 (A23).
23. Arteaga CL, O'Neil A, Moulder SL, et al. ECOG1100: a phase I-II study of combined blockade of the erbB receptor network with trastuzumab and gefitinib (Iressa) in patients (pts) with HER2-overexpressing metastatic breast cancer (met br ca). Breast Cancer Res Treat 2004;88:315 (A25).
24. Rusnak DW, Lackey K, Affleck K, et al The effects of the novel, reversible epidermal growth factor receptor/erbB2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in-vitro and in-vivo. Mol Cancer Ther 2001;1:85-94.
25. Xia W, Mullin R, Keith B, et al. Antitumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGFR activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways. Oncogene 2002;21:6255-63.
26. Spector N, Raefsky E, Hurwitz H, et al. Safety, clinical efficacy, and biological assessments from EGF10004; a randomised phase IB study of GW572016 for patients with metastatic carcinomas overexpressing EGFR or erbB2. Proc Am Soc Clin Oncol 2003;22:A772.
27. Chu I, Blackwell K, Chen S, Slingerland J. The dual ErbB1/ErbB2 inhibitor lapatinib (GW572016) cooperates with tamoxifen to inhibit both cell proliferation and estrogen-dependent gene expression in antiestrogen resistant breast cancer. Cancer Res 2005;65:18-25.
28. Blackwell KL, Kaplan EH, Franco SX, et al. A phase II, open-label, multicenter study of GW572016 in patients with trastuzumab-refractory metastatic breast cancer. Proc Am Soc Clin Oncol 2004;23:196 (A3006).
29. Blackwell KL, Burstein H, Pegram M, et al. Determining relevant biomarkers from tissue and serum that may predict response to single agent lapatinib in trastuzumab refractory metastatic breast cancer. Proc Am Soc Clin Oncol 2005;23:195s (A3004).
30. Gomez HL, Chavez MA, Doval DC, et al. A phase II randomized trial using the small-molecule tyrosine kinase inhibitor lapatinib as a first-line treatment in patients with FISH positive advanced or metastatic breast cancer Proc Am Soc Clin Oncol 2005;23:203s (A3046).
31. Chu Q, Goldstein L, Murray N, et al. A phase I, open label study of the safety tolerability and pharmacokinetics of lapatinib (GW572016) in combination with letrozole in cancer patients Proc Am Soc Clin Oncol 2005;23:192s (A3001).
32. Baselga J, Rojo F, Dumez H, et al. Phase I study of AEE788, a novel multi-targeted inhibitor of ErbB and VEGF receptor family tyrosine kinases. a pharmacokinetic (PK)-pharmacodynamic (PD) study to identify the optimal therapeutic dose regimen. Proc Am Soc Clin Oncol 2005;23:198s (A3028).
33. Hauge-Evans AC, Evans DB, Dowsett M, Martin L-A. Combining the RTK inhibitor AEE788 with tamoxifen or letrozoie results in enhanced growth inhibition of hormone dependent human breast cancer cells. Breast Cancer Res Treat 2004;8:S32 (A308).
34. Nemunaitis J, Eiseman I, Cunningham C, et al. Phase 1 clinical and pharmacokinetics evaluation of oral CI-1033 in patients with refractory cancer. Clin Cancer Res 2005;11:3846-53.
35. Yu K, Toral-Barza L, Discafani C, et al. mTOR, a novel target in breast cancer: the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 2001;8:249-58.
36. Rudolf J, Boulay A, Zumstem-Mecker S, Evans DB, O'Reilly T, Lane HA. The mTOR pathway in estrogen response: a potential for combining the rapamycin derivative RAD001 with the aromatase inhibitor letrozole in breast carcinomas. Proc Am Assoc Cancer Res 2004;45:A5619.
37. DeGraffenried LA, Friedrichs WE, Russel DH, et al. Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity. Clin Cancer Res 2004;10:8059-67.
38. Clark AS, West K, Streicher S, Dennis PA. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. Mol Cancer Ther 2002;1:707-17.
39. Pancholi S, Lykkesfeidt A, Dowsett M, Johnston SRD, Martin L-A. Elevated levels of Akt and p90rsk provide tamoxifen-resistant MCF-7 cells with a survival advantage involving Bad and Bcl-2. Proc Am Assoc Cancer Res 2004;45:A5168.
40. Chan S, Scheulen ME, Johnston SRD, et al. A phase II study of two dose levels of CCI-779 in locally advanced or metasatic breast cancer failing prior anthracyclines and/or taxanes regimens. J Clin Oncol 2005;23:5314-22.
41. Baselga J, Fumoleau P, Gil M, et al. Phase II, 3-arm study of CCI-779 in combination with letrozole in post-menopausal women with locally advanced or metastatic breast cancer: preliminary results. Proc Am Soc Clin Oncol 2004;23:13 (A544).
42. Carpenter JT, Roche H, Campone M, et al. Randomized 3-arm, phase 2 study of temsirolimus (CCI-779) in combination with letrozoie in postmenopausal women with locally advanced or metastatic breast cancer. Proc Am Soc Clin Oncol 2005;23:21s (A564).